Prospectus

INNOVATE Corp. Announces Further Extension of Rights Offering Subscription Period

Retrieved on: 
Tuesday, April 9, 2024
Form, Prospectus, Form S-3, Sale, Panzer corps

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today that its Board of Directors has extended the subscription period for its rights offering to 5:00 p.m. Eastern Time on April 19, 2024, in order to allow stockholders and noteholders who are entitled to participate in the rights offering (holders of record of the Company’s common stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and 2026 Convertible Notes as of 5:00 p.m. Eastern Time on March 6, 2024) additional time to participate.

Key Points: 
  • NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today that its Board of Directors has extended the subscription period for its rights offering to 5:00 p.m. Eastern Time on April 19, 2024, in order to allow stockholders and noteholders who are entitled to participate in the rights offering (holders of record of the Company’s common stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and 2026 Convertible Notes as of 5:00 p.m. Eastern Time on March 6, 2024) additional time to participate.
  • The rights offering was initially scheduled to expire at 5:00 p.m. Eastern Time on March 25, 2024 and the expiration date was previously extended until 5:00 p.m. Eastern Time on April 9, 2024.
  • The rights offering is being made pursuant to INNOVATE’s effective shelf registration statement on Form S-3, filed with the SEC on September 29, 2023 and declared effective on October 6, 2023, and a prospectus supplement containing the detailed terms of the rights offering originally filed with the SEC on March 8, 2024, as amended on March 23, 2024 and April 9, 2024.
  • The rights offering was made only by means of a prospectus and a related prospectus supplement, copies of which were distributed to all eligible rights holders as of the rights offering record date and may also be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the rights offering.

Great Elm Capital Corp. Announces Public Offering of Unsecured Notes

Retrieved on: 
Tuesday, April 9, 2024
City National Bank, Loan, PALM, Security agreement, Sale, Prospectus, Note, Investment, BEACH, Security (finance)

PALM BEACH GARDENS, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) announced today the commencement of an underwritten public offering of unsecured notes due 2029 (the “Notes”).

Key Points: 
  • PALM BEACH GARDENS, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) announced today the commencement of an underwritten public offering of unsecured notes due 2029 (the “Notes”).
  • The Notes are expected to be listed on The Nasdaq Global Market under the trading symbol “GECCI,” and to trade thereon within 30 days from the original issue date.
  • The interest rate and other terms of the Notes will be determined by negotiations between the Company and the underwriters.
  • Ladenburg Thalmann & Co. Inc., InspereX LLC, Janney Montgomery Scott LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Retrieved on: 
Tuesday, April 9, 2024
ACRV, Exchange, Health, Intelligence, Patient, Neoplasm, Paradigm, Research, AP3, Sale, Security (finance), Prospectus, Investment, Therapy, PIPE, Jefferies, Machine learning, Medicine

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.

Key Points: 
  • Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
  • The closing of the financing is expected to occur on April 11, 2024, subject to customary closing conditions.
  • “We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Jefferies acted as the exclusive placement agent in the private placement.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, and Anavex and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Form, Patient, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Rett syndrome, Prospectus, Complaint, P.C, Clinical trial, MCI, Radar, File, Register, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • For more information on the Anavex class action go to: https://bespc.com/cases/AVXL

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Longeveron Announces Pricing of $5.25 Million Public Offering

Retrieved on: 
Monday, April 8, 2024
3rd Floor, Form, Hypoplastic left heart syndrome, Sale, Public expenditure, Security (finance), HLHS, Prospectus

The closing of the offering is expected to occur on or about April 10, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about April 10, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $5.25 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering is being made only by means of a prospectus, which forms a part of the effective registration statement.
  • A preliminary prospectus relating to the public offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov .

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in HireRight Holdings Corporation of Class Action Lawsuit and Upcoming Deadlines – HRT

Retrieved on: 
Monday, April 8, 2024
Employment, Prior, Organization, Risk management, Hold, HireRight, Form, Risk, District court, Defendant, News, Ext, LLP, IPO, Alpha, Prospectus, Complaint, Publication, HRT, Pomerantz, Action Replay, Court, Register, Security (finance)

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) and certain officers.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Monday, April 8, 2024
Prior, Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages HireRight Holdings Corporation Investors to Secure Counsel in Securities Class Action – HRT

Retrieved on: 
Monday, April 8, 2024
Titan, Employment, HireRight, Risk, IPO, Prospectus, HRT, Advertising, Court

WHAT TO DO NEXT: To join the HireRight class action, go to https://rosenlegal.com/submit-form/?case_id=23874 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the HireRight class action, go to https://rosenlegal.com/submit-form/?case_id=23874 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AXT, Inc. - AXTI

Retrieved on: 
Monday, April 8, 2024
News, LLP, IPO, Prospectus, IP, AXT, Pomerantz

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AXT, Inc. (“AXT” or the “Company”) (NASDAQ: AXTI).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AXT, Inc. (“AXT” or the “Company”) (NASDAQ: AXTI).
  • The investigation concerns whether AXT and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.